Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
BioCryst Pharmaceuticals has won a $12 million, 18-month contract from the Department of Health & Human Services to support the development of the potential Ebola treatment BCX4430. The funds will enable the Durham, N.C.-based biotech firm to prepare for large-scale manufacturing of the antiviral, which is currently in Phase I studies to establish its safety. BCX4430 is the first small molecule for Ebola to receive funding from HHS. If extended through August 2017, BioCryst’s contract could be worth $35 million. Separately, an Ebola vaccine being developed by NewLink Genetics and Merck & Co. is safe and prompts an immune response, according to a clinical trial conducted by the National Institutes of Health.
This article has been sent to the following recipient: